Group 1 - The company approved a share repurchase plan with a total fund amount not less than RMB 18 million and not exceeding RMB 36 million, with a repurchase price cap of RMB 30.00 per share, valid for 12 months from the board's approval date [2] - The company later increased the repurchase fund amount to not less than RMB 36 million and not exceeding RMB 72 million, maintaining other aspects of the repurchase plan unchanged [3] - The company further adjusted the repurchase fund amount to not less than RMB 46 million and not exceeding RMB 80 million, extending the repurchase period by another 12 months until December 26, 2025 [4] Group 2 - The company modified the source of repurchase funds to include self-owned funds and a special loan from CITIC Bank, with the loan amount not exceeding RMB 34.65 million [5] - As of July 31, 2025, the company had repurchased a total of 2,505,324 shares, accounting for 3.09% of the total share capital, with a total payment of approximately RMB 42.5 million [6] - The company will adhere to relevant regulations and timely disclose information regarding the share repurchase progress [6]
天臣国际医疗科技股份有限公司关于股份回购进展公告